Inhibition of BRAF and MEK is standard-of-care targeted therapy for BRAFV600E melanoma, and the clinical response rate of BRAFV600E melanoma to combined BRAF/MEK inhibition is around 70%44. The gene discussed is MAP2K7; the disease is melanoma.